Indaptus Therapeutics, Inc. Profile Avatar - Palmy Investing

Indaptus Therapeutics, Inc.

Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable respo…

Biotechnology
US, New York [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Indaptus Therapeutics, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of INDP's Analysis
CIK: 1857044 CUSIP: 45339J105 ISIN: US45339J1051 LEI: - UEI: -
Secondary Listings
INDP has no secondary listings inside our databases.